# Predictions of Immunodominant Epitope Peptides From the AsaA Type VI Secretion System in Acinetobacter baumannii: A Computational Approach

## TL;DR

This study uses computational methods to identify potential vaccine targets from a protein in Acinetobacter baumannii, a dangerous antibiotic-resistant bacteria.

## Contribution

The study introduces a computational approach to predict immunodominant epitopes from the AsaA protein of A. baumannii for vaccine development.

## Key findings

- Epitope 1 (LILFLIGNY) showed strong binding to HLA alleles and is a promising vaccine candidate.
- Immune-dominant peptides were identified with high interaction potential with HLA and toll-like receptor.
- B-cell and T-cell epitopes were predicted using computational tools and molecular docking.

## Abstract

Introduction

Acinetobacter baumannii, designated as a priority pathogen by the World Health Organization (WHO), is responsible for recalcitrant infections in immunocompromised patients. The type VI secretion system (T6SS) is a class of macromolecular secretion machines, contributing to its virulence. The aim of this study is thus to predict the immune-dominant epitope peptides from the Acinetobacter T6SS-associated protein of A. baumannii (AsaA).

Methods

AsaA protein retrieval from the bacteria was carried out using computational platforms and the evaluation of antigenicity and allergenicity was performed. The T-cell epitopes of major histocompatibility complex class II binders were identified followed by molecular docking of the immune-dominant epitopes with human leukocyte antigen alleles using the ClusterPro server (https://cluspro.org/help.php). Additionally, the B-cell epitopes were predicted.

Results

Immune-informatic analysis showed immune-dominant peptides in the most favored regions with promising interactions with HLA alleles DP, DQ, DR, and toll-like receptor showing high binding capacity.

Conclusion

In the present investigation, epitope 1 (LILFLIGNY) was found to be a promising candidate for the synthesis of vaccines. However, it requires further experimentation for its immunological memory and response.